BMS’ Revlimid + Rituximab Receives EC’s Approval to Treat Adults Previously Treated Follicular Lymphoma (Grade 1-3a)

 BMS’ Revlimid + Rituximab Receives EC’s Approval to Treat Adults Previously Treated Follicular Lymphoma (Grade 1-3a)

BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

Shots:

  • The approval is based on P-III AUGUMENT study involves assessing of Revlimid + Rituximab (R2) vs rituximab +PBO in patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL)
  • The study resulted improvement in 1EP mPFS (39.4 mos. vs 13.8 mos.) with median follow up 29.2 months. Additionally, the safety and efficacy of Revlimid + Rituximab in patients with relapsed or refractory FL including rituximabrefractory FL patients was supported by MAGNIFY study
  • Revlimid (lenalidomide) + rituximab is the first chemotherapy-free combination regimen for patients with FL who have relapsed or did not respond to previous treatment and approved in the US, Canada, Switzerland, Australia, New Zealand and several Latin American countries

Click here to read full press release/ article | Ref: BMS | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post